Optimizing randomized phase II trials assessing tumor progression

Abstract The traditional development paradigm for phase II trials in oncology has been challenged in recent years by the introduction of cytostatic therapies. These agents slow the growth of tumors rather than cause high rates of shrinkage, this argues for the use of endpoints that measure growth in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Contemporary clinical trials 2007-02, Vol.28 (2), p.146-152
Hauptverfasser:	Stone, Andrew, Wheeler, Catherine, Carroll, Kevin, Barge, Alan
Format:	Artikel
Sprache:	eng
Schlagworte:	Algorithms Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Bias Biological and medical sciences Cancer Cardiovascular Clinical trial. Drug monitoring Clinical Trials, Phase II as Topic - methods Clinical Trials, Phase II as Topic - statistics & numerical data Disease Progression Disease-Free Survival General aspects General pharmacology Hematology, Oncology and Palliative Medicine Humans Medical sciences Models, Statistical Neoplasms - drug therapy Pharmacology. Drug treatments Phase II trials Randomization Randomized Controlled Trials as Topic - methods Randomized Controlled Trials as Topic - statistics & numerical data Research Design Sensitivity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!